Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Atoxlab
North Carolina, United Stateskr.linkedin.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Atox Bio is a late-stage clinical biotechnology company developing novel immunomodulators for critically ill patients with severe infections. Its lead candidate, Reltecimod (also known as AB103), has completed enrollment in a pivotal Phase 3 trial for necrotizing soft tissue infections and is also being studied in a registrational Phase 3 study for sepsis-associated acute kidney injury. The drug has received Orphan Drug designation from both FDA and EMA, as well as Fast Track designation from the FDA
- Therapeutic areas
- NephrologyInfectious Diseases
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Partnerships
BARDA/Biomedical Advanced Research and Development Authority contract worth up to $24 million for AB103 developmentYissum/Hebrew University technology licensing partnerInvestors include SR One, Lundbeckfond Ventures, OrbiMed Israel
Beyond the preview
Go deeper on Atoxlab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atoxlab.